ArticleDiabetology international2024
Food-induced small bowel obstruction observed in a patient with inappropriate use of semaglutide.
Article in Diabetology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials.International journal of molecular sciences · 2026Article
- Weighing the Risks: Small Bowel Obstruction Associated With Semaglutide Use in the Postoperative Abdomen.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We herein report a case of food-induced small bowel obstruction (FIBO) while using a glucagon-like peptide 1 receptor agonist (GLP1-RA), trying to lose weight due to distorted body image. The patient was a 30-year-old woman who was not obese (height 158 cm, weight 50 kg). She started taking an oral semaglutide, a GLP1-RA, and it was soon switched to weekly subcutaneous semaglutide because of ineffectiveness. More than 6 months after titrating up to 1.0 mg, she got drunk and chomped on a lot of scallops sandwiched between sheets of kelp, so-called "kobujime" in Japan, and half a day later complained of abdominal pain. Based on a finding of computed tomography at our emergency department, she was suspected of having a bowel obstruction and underwent laparoscopic surgery, which resulted in a diagnosis of small bowel obstruction by kelp. FIBO is rare, but it can become very severe once it happens. Although we cannot prove the direct pathophysiological effects of GLP1-RAs on FIBO in this particular case, GLP1-RAs have been reported to be one of the underlying risks of bowel obstruction based on epidemiological and basic research evidence; still, it is under-recognized. For example, the package inserts in Japan do not mention intestinal obstruction. We hope that the present report will prove helpful in paying attention to GLP1-RAs as a factor in bowel obstruction, including FIBO.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.